For how eGFR and albuminuria influence modern therapy choices, see SGLT2 inhibitors for kidney and heart protection.Summary: Albuminuria and estimated glomerular filtration rate, or eGFR, are the two core kidney markers used to detect and stage chronic kidney disease. In metabolic disease, they are also cardiovascular risk markers.

Why Kidney Markers Belong in Metabolic Disease

Kidney disease often travels with type 2 diabetes, hypertension, obesity, high uric acid, heart failure, and cardiovascular disease. The 2026 cardiovascular-kidney-metabolic framework places kidney risk at the center of metabolic medicine because CKD changes both prognosis and treatment choices.

What Albuminuria Means

Albuminuria means that albumin, a blood protein, is appearing in the urine. The usual screening test is a urine albumin-to-creatinine ratio, abbreviated UACR, from a spot urine sample. Albuminuria can be an early sign of kidney stress before eGFR falls.

The ADA Standards of Care classify urine albumin excretion as normal to mildly increased below 30 mg/g creatinine, moderately increased from 30 to less than 300 mg/g, and severely increased at 300 mg/g or higher. Because albuminuria varies, abnormal results are usually confirmed with repeat testing.

What eGFR Means

eGFR estimates kidney filtration from blood tests, usually serum creatinine, and sometimes cystatin C. A persistently reduced eGFR below 60 mL/min/1.73 m² is one way chronic kidney disease is identified. eGFR also affects medication dosing and treatment choices.

Why UACR and eGFR Should Be Read Together

A person can have albuminuria with preserved eGFR, reduced eGFR without much albuminuria, or both. The combination gives a better picture of kidney and cardiovascular risk than either marker alone.

Clinical Signals to Track

  • UACR, repeated when abnormal
  • eGFR trend over time
  • Blood pressure
  • A1C and glucose pattern
  • Uric acid when clinically relevant
  • Potassium when using ACE inhibitors, ARBs, MRAs, or related therapies
  • Medication choices, including SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone when appropriate

Bottom Line

Albuminuria and eGFR turn kidney risk into something measurable. For people with diabetes, hypertension, obesity, metabolic syndrome, or CKM syndrome, they help show whether the kidney is already involved in the metabolic disease pattern.

Sources: ADA, Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes 2026; AHA/ACC/ADA/ASN, 2026 CKM syndrome guideline.

Kidney Disease and Metabolic RiskType 2 DiabetesHypertensionCKM Syndrome

© 2026 Internets. All rights reserved.

Search